Cargando…
A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311388/ https://www.ncbi.nlm.nih.gov/pubmed/34285180 http://dx.doi.org/10.12659/AJCR.931478 |
_version_ | 1783728951311466496 |
---|---|
author | King, Eleanor R. Towner, Elizabeth |
author_facet | King, Eleanor R. Towner, Elizabeth |
author_sort | King, Eleanor R. |
collection | PubMed |
description | Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Here, we present a case of ITP as a complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT: Three days after receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old woman presented with a petechial rash on her trunk, legs, and arms, and fatigue and muscle aches. At the time of her hospital admission, her platelet count was 1000/µL. A peripheral smear showed profound thrombocytopenia. During the course of the patient’s hospitalization, she was treated with 2 units of platelets, 2 infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count increased to 92 000/µL on the day of discharge and she was prescribed a tapered dose of oral prednisone. One day later, her rash had resolved and her platelet count was 243 000/µL. The patient recovered completely with no complications. CONCLUSIONS: ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 vaccine. Knowing the early signs and symptoms of ITP will become increasingly important as more of the population receives this vaccine. Quick diagnosis and management are essential to avoid life-threatening bleeding. |
format | Online Article Text |
id | pubmed-8311388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83113882021-08-02 A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination King, Eleanor R. Towner, Elizabeth Am J Case Rep Articles Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Here, we present a case of ITP as a complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT: Three days after receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old woman presented with a petechial rash on her trunk, legs, and arms, and fatigue and muscle aches. At the time of her hospital admission, her platelet count was 1000/µL. A peripheral smear showed profound thrombocytopenia. During the course of the patient’s hospitalization, she was treated with 2 units of platelets, 2 infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count increased to 92 000/µL on the day of discharge and she was prescribed a tapered dose of oral prednisone. One day later, her rash had resolved and her platelet count was 243 000/µL. The patient recovered completely with no complications. CONCLUSIONS: ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 vaccine. Knowing the early signs and symptoms of ITP will become increasingly important as more of the population receives this vaccine. Quick diagnosis and management are essential to avoid life-threatening bleeding. International Scientific Literature, Inc. 2021-07-21 /pmc/articles/PMC8311388/ /pubmed/34285180 http://dx.doi.org/10.12659/AJCR.931478 Text en © Am J Case Rep, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles King, Eleanor R. Towner, Elizabeth A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination |
title | A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination |
title_full | A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination |
title_fullStr | A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination |
title_full_unstemmed | A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination |
title_short | A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination |
title_sort | case of immune thrombocytopenia after bnt162b2 mrna covid-19 vaccination |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311388/ https://www.ncbi.nlm.nih.gov/pubmed/34285180 http://dx.doi.org/10.12659/AJCR.931478 |
work_keys_str_mv | AT kingeleanorr acaseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination AT townerelizabeth acaseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination AT kingeleanorr caseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination AT townerelizabeth caseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination |